fbpx

Detecting Early Risk of Heart Failure in Saliva – CLEER

Detecting Early Risk of Heart Failure in Saliva – CLEER

About this clinical trial

Based on published research, evidence of specific biomarkers in saliva have been found to indicate an elevated risk of early Heart Failure. Identifying individuals at risk will help clinicians treat this disease early to lower hospitalisation, heart failures (Myocardial Infarction) and death rates caused by Heart Failure.

The trial will allow further development of a saliva test to detect individuals at risk of early Heart Failure.

Patients Required

Estimated completion

December 2022

Total participants required

80

Study location

The Wesley & St Andrew's War Memorial Hospitals

Trial title

Detecting Early Risk of Heart Failure in Saliva (CLEER) 

Eligibility

Inclusion Criteria:

  1. Subjects aged ≥50 years should have at least 2 of the following risk factors:
    • Established vascular disease 
    • Diabetes mellitus i or ii
    • Family history of vascular disease 
    • Atrial fibrillation 
    • Hypertension

OR

  1. Subjects aged ≥70 years should have at least 1 of the following risk factors: 
    • Established vascular disease
    • Diabetes mellitus i or ii 
    • Family history of vascular disease 
    • Atrial fibrillation 
    • Hypertension 

Lead investigator

Professor John Fraser

If you would like more information about this clinical trial, please complete the CLEER contact form

Name(Required)
Address(Required)

Wesley Medical Research

Scroll to Top